March 12, 2021 03:42 PM ESTUpdated March 15, 07:02 AM
Coronavirus

As­traZeneca ex­pects US vac­cine da­ta ‘soon’ — with 50M dos­es ready by the end of April

Zachary Brennan

Senior Editor

As­traZeneca said it’s ready­ing the re­lease of da­ta from its US-based Phase III tri­al, which has more than 32,000 par­tic­i­pants, for its up­com­ing emer­gency use …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times